Navigation Links
Two Luminaries Join Cequent Scientific Advisory Board: Judy Lieberman, M.D. Ph.D., and Patrice Courvalin, M.D.
Date:10/6/2008

Dr. Lieberman, of Harvard Medical School, is a prominent expert on RNAi delivery for therapeutic uses; Dr. Courvalin, of the Institut Pasteur,

Paris, France, is foremost authority on bacterial genetic transfer

CAMBRIDGE, Mass., Oct. 6 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that two of the leading scientists in RNA Interference (RNAi) and gene delivery have joined the company's scientific advisory board. Dr. Judy Lieberman, a professor at Harvard Medical School, is well-known for her pioneering work on RNAi delivery for clinical applications. Dr. Patrice Courvalin, who is Institut Pasteur professor and director of the French National Reference Center for Antibiotics, is a leading expert in molecular bacteriology and gene delivery.

"We are honored that Drs. Lieberman and Courvalin have agreed to join Cequent's scientific advisory board, which is chaired by Cequent Founder Chiang J Li, M.D.," said Cequent President and CEO, Peter Parker. "The two bring unparalleled expertise and experience in their respective areas of research so fundamental to our success. We continue to make great progress with our development programs for familial polyposis, human papilloma virus, and inflammatory bowel disease, and their input will be paramount as we advance our pipeline of RNAi drug candidates through preclinical development, regulatory submission, and into clinical trials."

Judy Lieberman, M.D. Ph.D., is professor of pediatrics at the Harvard Medical School, director of the Division of AIDS at Harvard Medical School, and a senior investigator in the Immune Disease Institute. She received a Ph.D. in theoretical physics from Rockefeller University and completed her M.D. in the joint Harvard-MIT Program in Health, Science and Technology. Dr. Lieberman is board certified in internal medicine and haematology, a widely known
'/>"/>

SOURCE Cequent Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
2. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
3. Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses
4. Thermo Fisher Scientific Executive Officers Adopting SEC Rule 10b5-1 Trading Programs
5. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
6. Ralf Rosskamp, M.D. Joins Biodels Scientific Advisory Board
7. Boston Scientific Amends Credit Facility and Prepays $1 Billion on Loan
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Thermo Fisher Scientific to Present at Investor Conferences
10. Boston Scientific to Participate in the Bear Stearns 20th Annual Healthcare Conference
11. Dr. Keith Wilson Named President and Chief Scientific Officer of Takeda San Diego

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)..., Most people would like to be able to charge the...kly and not too often. A recent discovery made by ...be-based supercapacitors that could do just this. ...sics Letters , Prabhakar Bandaru, a professor in t...ineering, along with graduate student Mark Hoefer,...
(Date:11/19/2009)..., , BLAUVELT, N.Y., Nov. 19 ...at germ extract, responds to a press release issue...he Hungarian company for making false and self-ser... BioSciences. ,, Dr. Hidvegi stated from his o... claim that research on Avemar does not apply to A...
(Date:11/19/2009)..., , BETHESDA, Md., Nov. 19 /PRNewswire-First... innovator in biotechnology for diabetes therapy, ...ing services to food, supplement, biotechnology an...sults of Tuesday,s Annual Meeting of Shareholders....orporated (Nasdaq: SPEX ) elected the following m...
(Date:11/19/2009)..., , MONTREAL, Nov. 19 /PRNewswire/ - Aegera ...e first patient in a randomized Phase 2B study of ...stage development for multiple oncology indication...ized Phase 2 Study of the X-Linked Inhibitor of Ap...tion with High-dose Cytarabine and Idarubicin in A...
Breaking Biology Technology:Nanotube defects equal better energy and storage systems 2American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor 2Spherix Announces Results of Annual Shareholders Meeting 2Spherix Announces Results of Annual Shareholders Meeting 3Spherix Announces Results of Annual Shareholders Meeting 4Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2
... Microbia, Inc. (formerly Microbia Prec...uction of sustainable, specialty ingredients and b...d that Alex Chu has joined the company as vice pre... vice president of manufacturing and process devel...obia,s process development and manufacturing initi...
...tical method that can estimate the origin and time... anthrax, following detection of the first few cas...cal Research Council (MRC) Centre for Outbreak Ana...collaboration with the Health Protection Agency,s ...escribed in an article published April 10 in the o...
... man with inoperable lung cancer is able to receiv..., , DOVER, N.H., May 26 Surgeons told Donald Bic...is lungs, ordinary surgery was not an option for r...ahadevan, MD, radiation oncologist at Wentworth-Do...asive radiosurgery using the Novalis Tx(TM) platfo...
Other Biology Technology:Microbia, Inc. Names Alex Chu as Vice President of Process Development 2Novel method predicts impact of a covert anthrax release 2Doctors in New Hampshire Now Treating Cancer with Non-Invasive Image-Guided Radiosurgery Using Novalis Tx(TM) Technology 2Doctors in New Hampshire Now Treating Cancer with Non-Invasive Image-Guided Radiosurgery Using Novalis Tx(TM) Technology 3
(Date:11/23/2009)... , , , , , , , ...Dr Andrew Marshall, from the Environment Departmen...ry of Kinyongia magomberae and his wider work in...e information. , , , , , ... , , , , , , A new species of chamele...
(Date:11/23/2009)...vironmental irritants such as air pollution and ci...ublished today in the American Journal of Respira...he study, from Imperial College London and the Uni...de the lungs that can trigger coughing when a pers...They suggest that their findings may ultimately le...
(Date:11/23/2009)...man . , Not just birds, but also a few speci...hers at Princeton University in the U.S. and at th...ll, Germany studied the migratory behaviour of the...pertilionidae" with the help of mathematical model...s well as long distances of various kinds of bats ...
Breaking Biology News(10 mins):New chameleon species discovered in East Africa 2New chameleon species discovered in East Africa 3Research reveals exactly how coughing is triggered by environmental irritants 2We're off then: The evolution of bat migration 2Announcing Companies to Present at the 7th Annual MidAmerica Healthcare Venture Forum 5079 1Announcing Companies to Present at the 7th Annual MidAmerica Healthcare Venture Forum 5079 2Announcing Companies to Present at the 7th Annual MidAmerica Healthcare Venture Forum 5079 3Announcing Companies to Present at the 7th Annual MidAmerica Healthcare Venture Forum 5079 4Kensey Nash to Present at the JMP Securities Fourth Annual Healthcare Focus Conference 58495 1AFGE Expresses Concern Over FEHBP Premium Increases 58493 1
... main source of food for many fish - including cod... to survive climate change. , Billions of Calanu...t a few millimetres in size, live in the waters of... out. , It showed they responded to global warmin... by moving north and maintaining large population ...
...rce, WALL, N.J., Sept. 23 BIO-key International,...r-based biometric,identification and wireless publ...e in the 2008 Biometric Technology Expo, to be hel...ference Consortium ("BCC") on,September 23 - 25 at...e,company will showcase a number of its fingerprin...
...s suffer a skin disorder called vitiligo, which ca...d other parts of the body. , A Loyola University ...ion federal grant to investigate a new way to trea... to new treatments for melanoma, the deadliest for...o-immune disease, in which the immune system goes ...
Other Biology News:Researchers find animal with ability to survive climate change 2BIO-key(R) to Showcase Biometric Security Applications at 2008 Biometric Technology Expo 2BIO-key(R) to Showcase Biometric Security Applications at 2008 Biometric Technology Expo 3Vitiligo skin disorder could yield clues in fight against melanoma 2
Equine TNF ALPHA from AbD Serotec
REact 2 Buffer from Invitrogen
Porcine TNF-alpha (TNFSF1A) ELISpot Development Kit from R&D Systems
5-bromo-4-chloro-3-indolyl b-D-galactopyranoside (X-Gal) from Molecular Probes (Invitrogen)
Biology Products: